The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors

Molecular Cell

Volumn 11, Issue 2, 2003, Pages 495-505

  Garrett, Thomas P J ^a   McKern, Neil M ^b   Lou, Meizhen ^a   Elleman, Thomas C ^b   Adams, Timothy E ^a,b   Lovrecz, George O ^a,b   Kofler, Michael ^b   Jorissen, Robert N ^a   Nice, Edouard C ^a   Burgess, Antony W ^a   Ward, Colin W ^a,b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b CSIRO   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DIMER; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; RECEPTOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CONFORMATION; CRYSTAL STRUCTURE; HUMAN; NONHUMAN; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN INTERACTION;

EID: 0037291226     PISSN: 10972765     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1097-2765(03)00048-0     Document Type: Article

References (58)

1. Bajaj M., Waterfield M.D., Schlessinger J., Taylor W.R., Blundell T. On the tertiary structure of the extracellular domains of the epidermal growth factor and insulin receptors. Biochim. Biophys. Acta. 916:1987;220-226.
2. Bebbington C.R., Hentschel C.C.G. The use of vector based on gene amplification for the expression of cloned genes in mammalian cells. Glover D. DNA Cloning. 1987;IRL Press, Oxford. 163-188.pp.
3. Berezov A., Zhang H.T., Greene M.I., Murali R. Disabling ErbB receptors with rationally designed exocyclic mimetics of antibodies. structure-function analysis J. Med. Chem. 44:2001;2565-2574.
4. Berezov A., Chen J., Liu Q., Zhang H.T., Greene M.I., Murali R. Disabling receptor ensembles with rationally designed interface peptidomimetics. J. Biol. Chem. 277:2002;28330-28339.
5. Brennan P.J., Kumogai T., Berezov A., Murali R., Greene M.I. HER2/neu. mechanisms of dimerization/oligomerization Oncogene. 19:2000;6093-6101.
6. Brizzard B.L., Chubet R.G., Vizard D.L. Immunoaffinity purification of FLAG epitope-tagged bacterial alkaline phosphatase using a novel monoclonal antibody and peptide elution. Biotechniques. 16:1994;730-735.
7. Brunger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., Jiang J.S., Kuszewski J., Nilges M., Pannu N.S.et al. Crystallography and NMR system. a new software suite for macromolecular structure determination Acta Crystallogr. D Biol. Crystallogr. 54:1998;905-921.
8. Cho H.S., Leahy D.J. Structure of the extracellular region of HER3 reveals an interdomain tether. Science. 297:2002;1330-1333.
9. Daly J.M., Jannot C.B., Beerli R.R., Graus-Porta D., Maurer F.G., Hynes N.E. Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells. Cancer Res. 57:1997;3804-3811.
10. de Bono J.S., Rowinsky E.K. The ErbB receptor family. a therapeutic target for cancer Trends Mol. Med. 8:2002;19-S26. Suppl) S.
11. Elleman T.C., Domagala T., McKern N.M., Nerrie M., Lonnqvist B., Adams T.E., Lewis J., Lovrecz G.O., Hoyne P.A., Richards K.M.et al. Identification of a determinant of epidermal growth factor receptor ligand-binding specificity using a truncated, high-affinity form of the ectodomain. Biochemistry. 40:2001;8930-8939.
12. Erickson S.L., O'Shea K.S., Ghaboosi N., Loverro L., Frantz G., Bauer M., Lu L.H., Moore M.W. ErbB3 is required for normal cerebellar and cardiac development. a comparison with ErbB2-and heregulin-deficient mice Development. 124:1997;4999-5011.
13. Ferguson K.M., Darling P.J., Mohan M.J., Macatee T.L., Lemmon M.A. Extracellular domains drive homo- but not heterodimerization of erbB receptors. EMBO J. 19:2000;4632-4643.
14. Ferguson K.M., Berger M.B., Mendrola J.M., Cho H.-S., Leahy D.J., Lemmon M.A. EGF activates its receptor by removing interactions that auto-inhibit ectodomain dimerization. Mol. Cell. 11:2003;507-517. this issue.
15. Garrett T.P.J., McKern N.M., Lou M.Z., Frenkel M.J., Bentley J.D., Lovrecz G.O., Elleman T.C., Cosgrove L.J., Ward C.W. Crystal structure of the first three domains of the type-1 insulin-like growth factor receptor. Nature. 394:1998;395-399.
16. Garrett T.P.J., McKern N.M., Lou M., Elleman T.C., Adams T.E., Lovrecz G.O., Hoyne P.A., Jorissen R.N., Nice E.C., Burgess A.W., Ward C.W. Crystal structure of the truncated epidermal growth factor receptor ectodomain bound to transforming growth factor α Cell. 110:2002;763-773.
17. Gassmann M., Casagranda F., Orioli D., Simon H., Lai C., Klein R., Lemke G. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature. 378:1995;390-394.
18. Graus-Porta D., Beerli R.R., Daly J.M., Hynes N.E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 16:1997;1647-1655.
19. Harari D., Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene. 19:2000;6102-6114.
20. Huizinga E.G., Tsuji S., Romijn R.A.P., Schiphorst M.E., de Groot P.G., Sixma J.J., Gros P. Structures of glycoprotein Ibα and its complex with von Willebrand factor A1 domain. Science. 297:2002;1176-1179.
21. Jancarik J., Kim S.-H. Sparse matrix sampling. a screening method for crystallization of proteins J. Appl. Crystallogr. 24:1991;409-411.
22. Jones J.T., Akita R.W., Sliwkowski M.X. Binding specificities and affinities of EGF domains for ErbB receptors. FEBS Lett. 447:1999;227-231.
23. Jones T.A., Zou J.Y., Cowan S.W., Kjeldgaard Improved methods for binding protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A. 47:1991;110-119.
24. King A.C., Cuatrecasas P. Resolution of high and low affinity epidermal growth factor receptors. Inhibition of high affinity component by low temperature, cycloheximide, and phorbol esters. J. Biol. Chem. 257:1982;3053-3060.
25. Kraus M.H., Issing W., Miki T., Popescu N.C., Aaronson S.A. Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family. evidence for overexpression in a subset of human mammary tumors Proc. Natl. Acad. Sci. USA. 86:1989;9193-9197.
26. Kumagai T., Davis J.G., Horie T., O'Rourke D.M., Greene M.I. The role of distinct p185neu extracellular subdomains for dimerization with the epidermal growth factor (EGF) receptor and EGF-mediated signaling. Proc. Natl. Acad. Sci. USA. 98:2001;5526-5531.
27. Lee K.F., Simon H., Chen H., Bates B., Hung M.C., Hauser C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature. 378:1995;394-398.
28. Lawrence M.C., Colman P.M. Shape complementarity at protein/protein interfaces. J. Mol. Biol. 234:1993;946-950.
29. Lax I., Johnson A., Howk R., Sap J., Bellot F., Winkler M., Ullrich A., Vennstrom B., Schlessinger J., Givol D. Chicken epidermal growth factor (EGF) receptor. cDNA cloning, expression in mouse cells, and differential binding of EGF and transforming growth factor alpha Mol. Cell. Biol. 8:1988;1970-1978.
30. Mendelsohn J., Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 19:2000;6550-6565.
31. Muthuswamy S.K., Muller W.J. Direct and specific interaction of c-Src with Neu is involved in signalling by the epidermal growth factor receptor. Oncogene. 11:1995;271-279.
32. Nicholls A., Sharp K., Honig B. Protein folding and association. insights from the interfacial and thermodynamic properties of hydrocarbons Proteins. 11:1991;281-295.
33. Ogiso H., Ishitani R., Nureki O., Fukai S., Yamanaka M., Kim J.-H., Saito S., Shirouzu M., Yokoyama S. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell. 110:2002;775-787.
34. Olayioye M.A., Neve R.M., Lane H.A., Hynes N.E. The ErbB signaling network. receptor heterodimerization in development and cancer EMBO J. 19:2000;3159-3167.
35. Orlandi R., Formantici C., Menard S., Boyer C.M., Wiener J.R., Colnaghi M. A linear region of a monoclonal antibody conformational epitope mapped on p185HER2 oncoprotein. Biol. Chem. 378:1997;1387-1392.
36. Otwinowski Z., Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276:1997;307-326.
37. Park B.W., Zhang H.T., Wu C.J., Berezov A., Zhang X., Dua R., Wang Q., Kao G., Orourke D.M., Greene M.I., Murali R. Rationally designed anti-HER2/neu peptide mimetic disables p185(HER2/neu) tyrosine kinases in vitro and in vivo. Nat. Biotechnol. 18:2000;194-198.
38. Penuel E., Akita R.W., Sliwkowski M.X. Identification of a region within the EerbB2/HER2 intracellular domain that is necessary for ligand-independent association. J. Biol. Chem. 277:2002;28468-28473.
39. Plowman G.D., Whitney G.S., Neubauer M.G., Green J.M., McDonald V.L., Todaro G.J., Shoyab M. Molecular cloning and expression of an additional epidermal growth factor receptor-related gene. Proc. Natl. Acad. Sci. USA. 87:1990;4905-4909.
40. Plowman G.D., Culouscou J.M., Whitney G.S., Green J.M., Carlton G.W., Foy L., Neubauer M.G., Shoyab M. Ligand-specific activation of HER4/p180ErbB4, a fourth member of the epidermal growth factor receptor family. Proc. Natl. Acad. Sci. USA. 90:1993;1746-1750.
41. Qian X., O'Rourke D.M., Fei Z., Zhang H.T., Kao C.C., Greene M.I. Domain-specific interactions between the p185(neu) and epidermal growth factor receptor kinases determine differential signaling outcomes. J. Biol. Chem. 274:1999;574-583.
42. Riethmacher D., Sonnenberg-Riethmacher E., Brinkmann V., Yamaai T., Lewin G.R., Birchmeier C. Severe neuropathies in mice with targeted mutations in the ErbB3 receptor. Nature. 389:1997;725-730.
43. Santra M., Reed C.C., Iozzo R.V. Decorin binds to a narrow region of the EGF receptor, partially overlapping with, but distinct from, the EGF-binding epitope. J. Biol. Chem. 277:2002;35671-35681.
44. Saxon M.L., Lee D.C. Mutagenesis reveals a role for epidermal growth factor receptor extracellular subdomain IV in ligand binding. J. Biol. Chem. 274:1999;28356-28362.
45. Schaefer G., Akita R.W., Sliwkowski M.X. A discrete three-amino acid segment (LVI) at the C-terminal end of kinase-impaired ErbB3 is required for transactivation of ErbB2. J. Biol. Chem. 274:1999;859-866.
46. Schechter A.L., Stern D.F., Vaidyanathan L., Decker S.J., Drebin J.A., Greene M.I., Weinberg R.A. The neu oncogene. an erb-B-related gene encoding a 185,000-Mr tumour antigen Nature. 312:1984;513-516.
47. Sharpe S., Barber K.R., Grant C.W.M. Val(659)-> Glu mutation within the transmembrane domain of ErbB-2. Effects measured by H-2 NMR in fluid phospholipid bilayers Biochemistry. 39:2000;6572-6580.
48. Sliwkowski M.X., Schaefer G., Akita R.W., Lofgren J.A., Fitzpatrick V.D., Nuijens A., Fendly B.M., Cerione R.A., Vandlen R.L., Carraway K.L. 3rd. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J. Biol. Chem. 269:1994;14661-14665.
49. Stanley P. Chinese hamster ovary cell mutants with multiple glycosylation defects for the production of glycoproteins with minimal carbohydrate heterogeneity. Mol. Cell. Biol. 9:1989;377-383.
50. Sundaresan S., Roberts P.E., King K.L., Sliwkowski M.X., Mather J.P. Biological response to ErbB ligands in nontransformed cell lines correlates with a specific pattern of receptor expression. Endocrinology. 139:1998;4756-4764.
51. Takagi J., Petre B.M., Walz T., Springer T.A. Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. Cell. 110:2002;599-611.
52. Ullrich A., Coussens L., Hayflick J.S., Dull T.J., Gray A., Tam A.W., Lee J., Yarden Y., Libermann T.A., Schlessinger J.et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature. 309:1984;418-425.
53. Ward C.W., Hoyne P.A., Flegg R.H. Insulin and epidermal growth factor receptors contain the cysteine repeat motif found in the tumor necrosis factor receptor. Proteins. 22:1995;141-153.
54. Wilkinson J.C., Staros J.V. Effect of ErbB2 coexpression on the kinetic interactions of epidermal growth factor with its receptor in intact cells. Biochemistry. 41:2002;8-14.
55. Yamamoto T., Ikawa S., Akiyama T., Semba K., Nomura N., Miyajima N., Saito T., Toyoshima K. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature. 319:1986;230-234.
56. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2:2001;127-137.
57. Yip Y.L., Ward R.L. Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines. Cancer Immunol. Immunother. 50:2002;569-587.
58. Yip Y.L., Smith G., Koch J., Dubel S., Ward R.L. Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies. implications for vaccine design J. Immunol. 166:2001;5271-5278.